Compare ULY & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ULY | LYRA |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.6M |
| IPO Year | N/A | 2020 |
| Metric | ULY | LYRA |
|---|---|---|
| Price | $2.15 | $1.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | $11.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 400.4K | 71.6K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $127,932,000.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.74 | $1.21 |
| 52 Week High | $17.99 | $37.50 |
| Indicator | ULY | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 29.93 |
| Support Level | $2.01 | $1.21 |
| Resistance Level | $2.23 | $2.05 |
| Average True Range (ATR) | 0.37 | 0.22 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 19.64 | 10.33 |
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.